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Abstract
Background: Transcription factor-mediated reprogramming can reset the epigenetics of somatic cells into a
pluripotency compatible state. Recent studies show that induced pluripotent stem cells (iPSCs) always inherit
starting cell-specific characteristics, called epigenetic memory, which may be advantageous, as directed
differentiation into specific cell types is still challenging; however, it also may be unpredictable when uncontrollable
differentiation occurs. In consideration of biosafety in disease modeling and personalized medicine, the availability
of high-quality iPSCs which lack a biased differentiation capacity and somatic memory could be indispensable.
Methods: Herein, we evaluate the hematopoietic differentiation capacity and somatic memory state of
hematopoietic progenitor and stem cell (HPC/HSC)-derived-iPSCs (HPC/HSC-iPSCs) using a previously established
sequential reprogramming system.
Results: We found that HPC/HSCs are amenable to being reprogrammed into iPSCs with unbiased differentiation
capacity to hematopoietic progenitors and mature hematopoietic cells. Genome-wide analyses revealed that no
global epigenetic memory was detectable in HPC/HSC-iPSCs, but only a minor transcriptional memory of HPC/HSCs
existed in a specific tetraploid complementation (4 N)-incompetent HPC/HSC-iPSC line. However, the observed
minor transcriptional memory had no influence on the hematopoietic differentiation capacity, indicating the
reprogramming of the HPC/HSCs was nearly complete. Further analysis revealed the correlation of minor
transcriptional memory with the aberrant distribution of H3K27me3.
Conclusions: This work provides a comprehensive framework for obtaining high-quality iPSCs from HPC/HSCs
with unbiased hematopoietic differentiation capacity and minor transcriptional memory.
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Background
Adult cells can be reverted into a pluripotent state by
forcing ectopic expression of a set of transcription fac-
tors, and the resulting induced pluripotent stem cells
(iPSCs) demonstrate differentiation potential into all
three germ layers [1]. iPSCs can be maintained at the
pluripotent state under defined culture conditions, hold-
ing great promise for regenerative medicine. However, the
reprogramming efficiency is always very low [2], indicating
that reprogramming is a complicated process. A recent
study has revealed a detailed route map of reprogram-
ming, demonstrating that reprogramming is not simply
the reversal of the normal developmental process [3]. Pre-
vious studies have revealed that the generation of iPSCs is
accompanied by a phenomenon called epigenetic memory,
and that the resulting iPSCs often inherit the epigenetic
characteristics of the starting cells and display a tendency
to differentiate toward the original cell lineage [4–7]. Simi-
lar results were obtained in another study, in which in-
complete reprogramming was discovered to be associated
with aberrant epigenetic modifications [8]. Compared with
other pluripotent stem cells, iPSCs retained more residual
DNA methylation patterns of parental somatic cells [9]. In
terms of biosafety concerns, the safety issues surrounding
epigenetic memory in reprogramming are not easy to
predict. It is noteworthy that the process of induced
reprogramming always coincided with the appearance of
cancer-related epigenetic abnormalities [10]. Therefore,
obtaining iPSCs with an unbiased differentiation capacity
and no somatic memory, and further characterization of
the underlying mechanisms of such reprogramming is im-
portant for the therapeutic use of such cells.
Hematopoietic cells have been widely used in tran-
scription factor-mediated reprogramming studies as
they are convenient to harvest [11, 12]. The well-
defined hematopoiesis hierarchy provides more infor-
mation for the derivation of hematopoietic cells from
progenitor cells or pluripotent cells, and it also works
as a good standard for evaluating the differentiation po-
tential of iPSCs [13]. Notably, epigenetic memory was first
discovered in the reprogramming of hematopoietic and
mesenchymal lineage cells [4]. Among hematopoietic pop-
ulations, hematopoietic progenitor and stem cells (HPC/
HSCs) have proven to be susceptible to transcription
factor-mediated reprogramming with high efficiency [13,
14]. Similarly, our previous study revealed that HPC/HSCs
are amenable to reprogramming, with a resulting high
frequency of high-quality HPC/HSC-iPSCs with full pluri-
potency [15]. Therefore, it is of interest to test whether
HPC/HSC-iPSCs manifest other outstanding characteris-
tics related to their differentiation capacity or novel mo-
lecular features.
In the present study, we aim to evaluate the differenti-
ation capacity and molecular features of HPC/HSC-iPSCs
under a previously established sequential reprogramming
system [16]. Our results reveal that HPC/HSCs are a novel
cell resource for obtaining iPSCs without biased differenti-
ation and epigenetic memory.
Methods
Cell culture
All embryonic stem cells (ESCs) and iPSCs were cultured
on mitomycin C-treated (Sigma-Aldrich, St. Louis, MO,
USA) mouse embryonic fibroblasts (MEFs) in ES medium,
which consisted of Dulbecco modified Eagle’s medium
(Invitrogen, Carlsbad, CA, USA) supplemented with 15%
fetal bovine serum (FBS; Hyclone, South Logan, UT,
USA), 1 mM L-glutamine (Invitrogen), 0.1 mM β-
mercaptoethanol (Invitrogen), 1% nonessential amino
acid (Invitrogen) and 1000 U/mL leukemia inhibitory
factor (EMD Millipore, Billerica, MA, USA).
Western blotting
RIPA buffer was used to prepare the cell extracts. Sam-
ples were resolved on SDS-PAGE gels, and transferred
to polyvinylidene fluoride membranes (BioRad. Hercules,
CA, USA). Specific proteins were further analyzed using
anti-Oct3/4 (Santa Cruz Biotechnology, Dallas, TX,
USA), anti-Sox2 (Abcam, Cambridge, UK), anti-Klf4
(R&D Systems, Minneapolis, MN, USA), anti-c-Myc
(Abcam) and anti-Gapdh (Sigma-Aldrich) antibodies.
Peroxidase-labeled anti-mouse, rabbit or goat antibodies
labeled with enhanced chemiluminescence (GE Health-
care, Chicago, IL, USA) were used for further detection.
Hematopoietic differentiation of iPSCs and ESCs
An OP9 co-culture assay was performed as previously
described [17]. OP9 stromal cells were plated onto gelati-
nized 100-mm dishes in α-MEM (Invitrogen) containing
20% FBS (Hyclone), 2 mM L-glutamax (Invitrogen) and
1% penicillin/streptomycin (EMD Millipore). Feeder-free
ESCs or iPSCs were replated in dishes where OP9 cells
had formed confluent cultures on day 6 at a density of
1.5 × 106 per 100-mm dish in α-MEM (Invitrogen) supple-
mented with 10% FBS (HyClone) and 100 μM monothio-
glycerol (MTG; Sigma-Aldrich). The co-cultured cells
were incubated for another 8 days with a half-medium
change every other day. Single-cell suspensions were
prepared for flow-cytometry analysis on day 8.
A hematopoietic colony-forming assay was performed
using a standard kit (Stemcell Technologies, Vancouver,
BC, USA). In brief, ESCs and iPSCs were cultured on
gelatin-coated dishes for two passages to remove MEFs
prior to embryonic body (EB) differentiation, and feeder-
free ESCs and iPSCs were harvested by centrifugation at
200 × g for 5 min. The cell pellet was resuspended in dif-
ferentiation medium, containing 15% FBS, 1% penicillin/
streptomycin, 1% L-glutamine (Invitrogen), 150 μM MTG
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(Sigma-Aldrich), 100 μM ascorbic acid-vitamin C (Sigma-
Aldrich) and hematopoietic growth factors at a density of
4 × 105/25 mL. To form EBs, the cells in “Reagent Reser-
voirs” were then transferred to the covers of 15-cm dishes
using a multichannel pipette; each drop had a volume of
25 μL. Four days later, EBs were collected from the hang-
ing drops and transferred to an ultra-low attachment dish
to continue the differentiation process. Hematopoietic
colony assays were performed using 50,000 D6 EB cells
in hematopoietic differentiation medium. Colony-
forming units (CFUs) were counted from three experi-
ments for erythrocytes (BFU-E), macrophages (M),
granulocyte-macrophages (GM) and granulocyte-
erythrocyte-macrophage-megakaryocytes (GEMM) after
10–14 days of culture. The medium and additional
components used here are all listed in the Stemcell
Technologies technical manual.
Flow cytometry analysis
To analyze the differentiation capacity to hematopoietic
progenitors, ESCs/OP9 and iPSCs/OP9 co-cultured cells
were collected and washed using fluorescence-activating
cell sorting (FACS) buffer (phosphate-buffered salt solu-
tion with 2% FBS). Cells were then stained using an anti-
mouse SSEA-1-Alexa Fluor 647 monoclonal antibody
(eBioscience, San Diego, CA, USA), an anti-mouse c-Kit-
APC monoclonal antibody (eBioscience), an anti-mouse
Sca-1-PE/Cy7 monoclonal antibody (eBioscience) and an
anti-mouse CD34-Alexa Fluor PE monoclonal antibody
(eBioscience) in different combinations. After the staining,
cells were washed and resuspended in FACS buffer. Gat-
ing was performed using matched isotype control mono-
clonal antibodies. Fluorescent-activated cell analyses were
performed using a MoFlo XDP cell sorter (Beckman
Coulter Inc., Brea, CA, USA).
For the analyses of ESCs/OP9 and iPSCs/OP9 co-
cultures, the differentiated states of ESCs or iPSCs were
first analyzed according to the expression of SSEA-1 on
day 8. Then, cells with large diameters were removed
first and GFP-positive cells (OP9) were removed next.
Finally, c-Kit+Sca-1+ double-positive cells were divided
into two subpopulations for the analysis of long-term
and short-term HSCs based on the expression of CD34.
RNA sequencing (RNA-Seq), methylated DNA
immunoprecipitation sequencing (MeDIP-Seq) and
chromatin immunoprecipitation sequencing (ChIP-Seq)
The sample preparation, library generation, and sequence
analysis of RNA-Seq, MeDIP-Seq, and ChIP-Seq were all
in accordance with our previously reported methods [18].
In general, the sequencing was performed at the Beijing
Genomics Institute using the HiSeq 2000 system
(Illumina, San Diego, CA, USA). Single-end sequencing
was applied to RNA-Seq and ChIP-Seq. Paired-end se-
quencing was applied to MeDIP-Seq.
Bioinformatics analyses
The MeDIP/ChIP-Seq reads were mapped to the mouse
reference genome (mm9/NCBI37) using Bowtie
(v0.12.7) allowing the max mismatch of 3 nt [19]. The
RNA-Seq reads were mapped to the mouse genome
using Tophat (v1.3.3) and the Ensembl genome annota-
tion (Mus_musculus.NCBIM37.64.gtf ) [20]. Cufflink
(v1.2.0) software was used to analyze the mRNA ex-
pression patterns (FPKM, fragments per kilobase of
exon per million fragments mapped) as previously de-
scribed [21]. MACS (v1.4.1) software was used to iden-
tify regions enriched for DNA methylation (peaks)
using the default parameters [22]; the cutoff P value
was set at 1 × 10-5. CCAT (v3.0) software was used to
identify histone modification-enriched regions (peaks)
using the parameters as previously reported [23]; the
FDR cutoff was set at 0.05.
For the transcriptional memory analysis in HPC/
HSC-iPSCs, we first identified genes specifically
expressed by HPC/HSCs using two cell types as con-
trols. The genes with low expression were filtered out
using a standard of FPKM ≥10 in at least one sample.
ANOVA was then applied to identify genes that were
significantly differentially expressed in the somatic sam-
ples. HPC/HSC-specific genes were extracted only if
the FPKM values of the genes were twofold higher or
lower in HPC/HSCs than in any other cell line. Genes
that were differentially expressed in HPC/HSC-iPSC
lines were then identified and compared with HPC/
HSC-specific genes. The overlapping gene sets were an-
alyzed using Gene Ontology (GO) tools (DAVID) to
identify enriched GO terms [24]. Normalized 5mC,
H3K4me2, H3K4me3, and H3K27me3 read counts in
the transcription start site (TSS) ± 2 kb regions of dif-
ferent gene sets were represented using the R boxplot
function.
Statistical analyses
Data was analyzed by the GraphPad Prism5 (GraphPad
Software, Inc, La Jolla, CA, USA). The experiments were
repeated independently three times. Statistical differences
were evaluated using the Student’s t test as indicated.
Standard deviation (SD) was used to assess biological
significance.
Accession numbers
The GEO accession number for the genome-wide se-
quencing data reported in this article is GSE36294.
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Results
Unique histone modification patterns in HPC/HSC-specific
genes and the stoichiometry of transcription factors in
the reprogramming of HPC/HSCs
Under the previously established sequential reprogram-
ming system [16], HPC/HSCs were found to be amenable
to reprogramming into high-quality iPSCs with full pluri-
potency [15]. It is also of interest to know whether the re-
programming of HPC/HSCs could give rise to iPSCs with
unbiased differentiation and no somatic memory. To this
aim, integrated analysis of hematopoietic differentiation
outcomes and molecular characterization of HPC/HSC-
iPSCs was performed in the present study (Fig. 1a).
The epigenetic memory of iPSCs detailed in previous
studies has always been associated with the expression
of starting cell-specific genes [4, 5]. Therefore, it is of
interest to understand the molecular features of HPC/
HSC-specific genes, which may determine the reprogram-
ming process and the differentiation capacity of HPC/
HSC-iPSCs. First, global gene expression patterns were
compared among HPC/HSCs, MEFs, R1, and iPSCs (10-
MEF-iPSC-37). Hierarchical clustering analyses show that
Fig. 1 Genome-wide cellular characteristics of HPC/HSCs and OSKM-mediated reprogramming of HPC/HSCs. a Schematic showing the generation
of HPC/HSC-iPSCs and the evaluation of hematopoietic differentiation potential and genome-wide memory status. b Hierarchical clustering of
genome-wide gene expression patterns of HPC/HSCs, MEFs, R1 ESCs and iPSCs. The analysis of each cell line was repeated twice. c Distribution of
DNA methylation (5mC) and histone modifications (H3K4me2, H3K4me3, and H3K27me3) in the TSS ± 2 kb regions of genes with high expression
in HPC/HSCs. The normalized read counts in HPC/HSCs minus the counts in MEFs were used for the plots. d Distribution of DNA methylation
(5mC) and histone modifications (H3K4me2, H3K4me3, and H3K27me3) in the TSS ± 2 kb regions of genes with low expression in HPC/HSCs. The
normalized read counts in HPC/HSCs minus the counts in MEFs were used for the plots. e Western blot comparing the expression levels of the
four reprogramming factors in OSKM-mediated reprogramming in the isolates of HPC/HSCs and MEFs. 4 N tetraploid complementation, HPC/HSC
hematopoietic progenitor and stem cell, iPSC induced pluripotent stem cell, MEF mouse embryonic fibroblast, RNA-Seq RNA sequencing. f The
read distribution of RNA-Seq, H3K27me3, H3K4me3, H3K4me2 ChIP-Seq and DNA methylation (5mC) in the region corresponding to the upstream
region of the Dlk1-Dio3 locus in R1, MEFs, and HPC/HSCs. Scale bar, 30 kb
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HPC/HSCs have differential gene expression patterns
compared with MEFs and pluripotent stem cells
(Fig. 1b). HPC/HSC-specific genes were screened out
by comparing the gene expression patterns between
HPC/HSCs and MEFs. To investigate the regulatory
mechanisms underlying the differential expression of
these genes, high-throughput sequencing was per-
formed to investigate the DNA methylation (5mC) and
core histone modifications (H3K4me2, H3K4me3, and
H3K27me3) near the TSS of the HPC/HSC-specific
genes. We found that DNA methylation was not associ-
ated with the expression of these two gene groups
(Fig. 1c, d). However, H3K4me3 and H3K4me2 were
found to be enriched in the TSS of the highly expressed
HPC/HSC genes but absent from that of the lowly
expressed HPC/HSC genes. However, H3K27me3 showed
a contrasting pattern, being enriched in the TSS of highly
expressed HPC/HSC genes but absent from that of lowly
expressed HPC/HSC genes (Fig. 1c, d). Interestingly, the
presence or absence of H3K4me3 and H3K4me2 was syn-
chronous for the TSS of most differentially expressed
genes. Therefore, the observed reciprocal occupancy of
H3K4me2/H3K4me3 and H3K27me3 may inversely regu-
late the expression of HPC/HSC-specific genes, which is
in contrast to the bivalent histone modification profiles
found in embryonic stem cells [25]. In summary, our
results show that balanced occupancy of H3K4me3/
H3K4me2 and H3K27me3 may play an important role in
controlling the expression patterns of HPC/HSC-specific
genes.
Another feature of HPC/HSC reprogramming is the
high frequency of iPSCs with full pluripotency, as we pre-
viously reported [15]. It has been demonstrated that the
stoichiometry of reprogramming factors has a great influ-
ence on the quality of iPSCs [26]. Therefore, the stoichi-
ometry of transcription factors during the reprogramming
process of HPC/HSCs was compared, and it was found
that intermediate cells of the HPC/HSC reprogramming
showed higher expression of Oct4, Sox2, Klf4, and c-Myc
than their counterparts during MEF reprogramming
(Fig. 1e). Of note, differential transcription factor stoichi-
ometry was observed only during the reprogramming
process but not in the starting cells, demonstrating that
the roadmap of HPC/HSC reprogramming is unique com-
pared with that of MEFs.
To test whether the observed particular core histone
modifications (H3K4me3, H3K4me2, and H3K27me3)
occupancy patterns exist in specific gene loci, we exam-
ined the epigenetic modifications of Dlk1-Dio3, which
was found to be associated with the pluripotency state
of iPSCs [27, 28]. The results show that the RNA-Seq
profile at the Dlk1-Dio3 locus of HPC/HSCs is dramatic-
ally different from that of MEFs (Fig. 1f). In accordance
with genome-wide similarities of DNA methylation, the
distribution of the 5mC signal at this locus showed no
difference between HPC/HSCs and MEFs (Fig. 1f ).
However, core histone modifications (H3K4me2,
H3K4me3 and H3K27me3) were found to be differen-
tially distributed at the Dlk1-Dio3 locus between HPC/
HSCs and MEFs. Notably, the absence of RNA-Seq read
distribution in the HPC/HSCs corresponded to the en-
richment of H3K27me3 and the decrease of H3K4me3,
which was generally consistent with the previously dis-
cussed global core histone modifications (H3K4me2,
H3K4me3, and H3K27me3) patterns in HPC/HSC-spe-
cific genes. In addition, the core histone modifications
(H3K4me2, H3K4me3, and H3K27me3) in both HPC/
HSCs and MEFs were distinguishable from that of
iPSCs and R1, indicating that the starting cells from dif-
ferent origins undergo distinct epigenetic reprogram-
ming to achieve a pluripotent state. In support of this
result, a recent study that re-interpreted our small
RNA sequencing dataset [18] revealed a unique repro-
gramming process of HPC/HSCs, in which some
lncRNAs were distinctively activated to repress HPC/
HSC-lineage-specific genes [29].
Together, HPC/HSC-specific genes were found be
modified with unique reciprocal occupancy of H3K4me2/
H3K4me3 and H3K27me3. The reprogramming process
of HPC/HSCs demonstrates a specific stoichiometry of
transcription factors, in which Oct4, Sox2, Klf4, and c-
Myc are highly expressed compared with that of MEFs.
Unbiased hematopoietic differentiation capacity of HPC/
HSC-iPSCs
As mentioned above, core histone modifications
(H3K4me2, H3K4me3, and H3K27me3) patterns in
HPC/HSC-iPSCs and the transcription factor stoichi-
ometry in HPC/HSC reprogramming were examined.
However, it is unknown whether these molecular fea-
tures could facilitate the overcoming of reprogramming
barriers to achieve complete reprogramming, which
may result in iPSCs with unbiased differentiation cap-
acity and no somatic memory of the starting cells.
Recent findings have suggested that hematopoietic cell-
derived iPSCs retain a biased differentiation tendency
toward the cell lineage of their starting cells, which
results from epigenetic memory [4, 5]. To assess the
differentiation capacity of HPC/HSC-iPSCs, in vitro
hematopoietic differentiation was performed in the four
HPC/HSC-iPSC lines, five mesenchyme-derived iPSC
lines (M-iPSCs) and one ESC line (R1). To eliminate
the influence of continuous passaging of iPSCs on their
epigenetic memory, the iPSC lines used for the differenti-
ation assays here were all at an early passage (<p8) stage,
which is consistent with previous studies [4, 5].
An OP9 co-culture system was used to evaluate the dif-
ferentiation capacity of HPC/HSC-iPSCs and M-iPSCs to
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hematopoietic cells, as previously described [17], and this
was implemented using a hierarchical cell-sorting analysis
during flow cytometry (Fig. 2a). In the OP9 co-culture
system, typical differentiated iPSCs/ESCs could be easily
distinguished from GFP-positive OP9 stromal cells
(Fig. 2b). We found that HPC/HSC-iPSCs yielded a simi-
lar frequency of SSEA-1+ cells when cultured on mitomy-
cin C-treated MEFs or 8 days after differentiation by co-
culture with OP9 cells, compared with the frequency of
SSEA-1+ M-iPSCs (Fig. 2c and Additional file 1: Figure
S1). Hierarchical cell sorting was performed based on spe-
cific cell lineage markers, and the GFP-positive cells
(OP9) were discarded first (Additional file 2: Figure S2).
GFP-negative cells were maintained for further isolation
of Sca-1+ and c-Kit+ cells. We found that similar pro-
portions of Sca-1+ and c-Kit+ cells were differentiated
from both HPC/HSC-iPSCs and M-iPSCs (Fig. 2d).
Finally, c-Kit+Sca-1+ cells, which contained the HPC/
HSCs were further analyzed and we detected comparable
proportions of c-Kit+Sca-1+CD34+ cells (short-term
HSCs) and c-Kit+Sca-1+CD34- cells (long-term HSCs)
from both the HPC/HSC-iPSCs and M-iPSCs (Fig. 2d).
Therefore, HPC/HSC-iPSCs and M-iPSCs had a similar
capacity to differentiate into progenitors of hematopoietic
cells.
To further test whether HPC/HSC-iPSCs preferen-
tially differentiate into mature hematopoietic cells,
hematopoietic colony-forming capacity was evaluated
in HPC/HSC-iPSCs and M-iPSCs. First, EBs were gen-
erated from HPC/HSC-iPSCs and M-iPSCs, which had
similar morphology and size (Fig. 3a). Then, the cells
which dissociated from mature EBs were further differ-
entiated in hematopoietic differentiation medium, and
typical hematopoietic colonies could be observed
(Fig. 3b). The results show that HPC/HSC-iPSCs and
M-iPSCs yielded similar numbers of the four types of
hematopoietic colonies (Fig. 3c, d). In summary, the in
vitro hematopoietic differentiation results reveal that
Fig. 2 HPC/HSC-iPSCs showed unbiased differentiation potential into hematopoietic progenitor cells. a Schematic illustration of the flow cytometry
analysis. b Typical cell morphology of ESCs and iPSCs co-cultured with OP9 stromal cells. Left, bright field; GFP, the field under fluorescence microscopy
with an excitation peak of 488 nm. c Expression of SSEA-1 by ESCs and iPSCs as detected using flow cytometry after co-culture with OP9 stromal cells
for 8 days. Error bars indicate the SD P, P value, unpaired t test. d Differentiation efficiency of ESCs and iPSCs into different types of hematopoietic
progenitor cells; Error bars indicate the SD P, P value, unpaired t test. HPC/HSC hematopoietic progenitor and stem cell, iPSC induced pluripotent stem
cell, SD standard deviation
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iPSCs derived from HPC/HSCs manifested an apparently
unbiased differentiation capacity to both hematopoietic
progenitor cells and mature hematopoietic cells compared
with that of MEFs.
Minor transcriptional memory retained in specific HPC/
HSC-iPSCs
Our previous study demonstrated that a large propor-
tion of HPC/HSC-iPSC lines manifest full pluripotency,
which is only one symbol of complete reprogramming
[15]. Based on the hematopoietic differentiation results
described above, HPC/HSC-iPSCs have an unbiased
differentiation capacity to both hematopoietic progeni-
tor cells and mature hematopoietic cells. Therefore, the
reprogramming of HPC/HSCs appears complete, and
could enable the production of high-quality iPSCs with
full pluripotency and an unbiased differentiation capacity.
However, it remains unclear whether HPC/HSC-iPSCs re-
tain a somatic memory state of their starting cells.
To this end, genome-wide analyses were performed
to test whether a residual somatic memory exists in
HPC/HSCs-iPSCs. First, the global memory of starting
cells was compared between HPC/HSC-iPSCs and
other origin-derived iPSCs; it was found that no global
memory was detectable in the HPC/HSC-iPSCs based
on our previous genome-wide sequencing analyses data
[18]. We analyzed the global gene expression profiles of
MEFs, adipose progenitor cells (APCs) and HPC/HSCs.
The HPC/HSC-specific genes were identified through the
comparison of HPC/HSCs with MEFs and APCs, two cell
types that originate from mesenchymal stem cells, and are
used as a reference for further comparisons in memory-
related analysis. The differentially expressed genes in the
two HPC/HSC-iPSC lines, the 20-HPC/HSC-iPSC-16
(4 N-ON) and the 20-HPC/HSC-iPSC-18 (4 N-OFF) line,
Fig. 3 HPC/HSC-iPSCs showed unbiased differentiation potential into hematopoietic mature cells. a Embryonic bodies derived from early-passage
mesenchyme-iPSCs and HPC/HSC-iPSCs; scale bars, 200 μm. b Representative hematopoietic colonies derived from iPSCs with Wright–Giemsa
staining to reveal the hematopoietic progenitors. From left to right: BFU-E erythrocyte, M macrophage, GM granulocyte-macrophage, and GEMM
granulocyte-erythrocyte-macrophage-megakaryocyte. Scale bars: top, 100 μm; bottom, 40 μm. c In vitro hematopoietic colony number per 50,000 cells
of EBs differentiated from mesenchyme-iPSCs (n = 5) and hematopoietic-iPSCs (n = 4), using R1 cells as a control. The error bars indicate SD. d The
comparison of CFU numbers between mesenchyme-iPSCs and hematopoietic-iPSCs (n = 3 measurements). Error bars indicate the SD P, P value,
unpaired t test. EB embryonic body, HPC/HSC hematopoietic progenitor and stem cell, iPSC induced pluripotent stem cell, CFU colony-forming unit
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were also screened, and the expression patterns of these
differentially expressed genes were further analyzed and
compared with the genes specifically expressed in HPC/
HSCs to determine which iPSC line most closely resem-
bled HPC/HSCs. In this analysis, 2910 genes were found
to be specifically expressed in HPC/HSCs (1340 genes
with high expression and 1570 genes with low expression).
Interestingly, the 20-HPC/HSC-iPSC-18 line more closely
resembles HPC/HSCs than the 20-HPC/HSC-iPSC-16 line
in terms of gene expression patterns; notably, its gene ex-
pression pattern clusters with the HPC/HSC lowly
expressed genes (Fig. 4a). We found 310 genes to be at
least twofold more highly expressed in the 20-HPC/HSC-
iPSC-18 line than in the 20-HPC/HSC-iPSC-16 line
(Fig. 4b); likewise, 610 genes were found to be at least
twofold more highly expressed in the 20-HPC/HSC-iPSC-
16 line than in the 20-HPC/HSC-iPSC-18 line (Fig. 4c,
top). Notably, among the 610 lowly expressed genes found
in the 20-HPC/HSC-iPSC-18 line, the expression of 332
genes overlapped with the gene expression pattern of
the HPC/HSCs, indicating that the 20-HPC/HSC-
iPSC-18 line retained some transcriptional characteris-
tics of the HPC/HSCs (Fig. 4c, top). Additionally, the
most enriched GO term associated with the overlap-
ping 332 genes indicated correlation of these genes
with hematopoietic functions such as “vasculature
development” and “blood vessel development” (Fig. 4c,
bottom). Similarly, of the 310 highly expressed genes
in the 20-HPC/HSC-iPSC-18 line, 25 genes also over-
lapped with those of the HPC/HSCs, a greater number
than that observed in the 20-HPC/HSC-iPSC-16 line
(13 genes; Fig. 4b). However, these 25 genes were not
sufficient to reveal any enriched GO category. These
findings demonstrate that minor transcriptional mem-
ory was retained in the 20-HPC/HSC-iPSC-18 line,
suggesting that incomplete reprogramming may occur
in some 4 N-incompetent HPC/HSC-iPSCs.
To know whether the minor transcriptional memory
was prevalent in iPSCs from other origins, two iPSC
lines, 10-MEF-iPSC-37 and 10-MEF-iPSC-42, were also
randomly selected to confirm whether similar minor
transcriptional memory was retained in MEF-iPSCs. In
agreement with our previous report [18], the 10-MEF-
iPSC-37 and 10-MEF-iPSC-42 lines were indistinguish-
able at the level of genome-wide gene expression
(Additional file 3: Figure S3A, B). However, neither
minor transcriptional memory nor remarkable GO re-
sults were observed for these two iPSC lines, indicating
that the observed transcriptional memory in the HPC/
HSC-iPSC line occurred randomly and was not inher-
ent to every iPSC line (Additional file 3: Figure S3C).
Together, these results show that HPC/HSC-iPSCs and
MEF-iPSCs derived from our sequential reprogram-
ming system have no obvious memory of starting cells;
nevertheless, minor residual transcriptional memory is
retained in specific 4 N-incompetent HPC/HSC-iPSCs.
H3K27me3 correlates with the minor transcriptional
memory of HPC/HSC-iPSCs
To elucidate the reason for the minor transcriptional
memory, epigenetic modifications near the TSS for these
transcriptional memory-related genes were examined.
Among the epigenetic modifications, 5mC, H3K4me2 and
H3K4me3 showed no obvious difference in the TSS of
these genes between 20-HPC/HSC-iPSC-18 and 20-HPC/
HSC-iPSC-16 (Fig. 4d). However, intense H3K27me3
signals that deviate from random sampling were observed
in 20-HPC/HSC-iPSC-18 compared with 20-HPC/HSC-
iPSC-16, which may account for the repression of genes
with minor transcriptional memory (Fig. 4d).
Collectively, the work presented here shows that
HPC/HSCs are amenable to reprogramming through
the use of a sequential reprogramming system into
iPSCs with an unbiased hematopoietic differentiation
capacity and no global epigenetic memory. Genome-wide
analyses revealed that only a specific 4 N-incompetent
HPC/HSC-iPSC line carried a minor transcriptional
memory of starting cells, which had no influence on the
differentiation capacity to hematopoietic progenitors and
mature hematopoietic cells. Further analysis revealed that
the aberrant distribution of H3K27me3 is associated with
the observed minor transcriptional memory.
Discussion
In the present study, HPC/HSC reprogramming was in-
vestigated, in terms of its molecular features and their
effects on differentiation capacity. To the best of our
knowledge, this study is the first demonstration that
HPC/HSCs are amenable to be reprogrammed into
iPSCs with unbiased hematopoietic differentiation
capacity and no global epigenetic memory. However, a
specific 4 N-incompetent HPC/HSC-iPSC line retained
minor transcriptional memory of the starting cells,
which had no influence on the hematopoietic differen-
tiation capacity. Through genome-wide analysis, we
found balanced occupancy of H3K4me3/H3K4me2 and
H3K27me3 in HPC/HSC-specific genes, suggesting that
histone modification transition is indispensable for
HPC/HSC reprogramming. Furthermore, we discovered
the correlation between the aberrant distribution of
H3K27me3 and minor transcriptional memory.
The biosafety of iPSCs determines the future of cell
transplantation-based regenerative medicine, and it is
supposed that the quality of iPSCs can be improved by
altering reprogramming strategies. It is noteworthy that
totipotent iPSCs can be obtained by optimizing induction
conditions [30, 31]. Moreover, the addition or substitution
of specific reprogramming-related genes under traditional
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Fig. 4 (See legend on next page.)
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reprogramming conditions has been shown to give rise
to more pluripotent iPSCs [32, 33]. The transcription
factor-mediated cell fate reversion from somatic cells to
pluripotent cells is accompanied by epigenetic transi-
tions, in which the epigenetic state of the starting cells
must be adjusted to a pluripotency compatible state [2].
A bivalent histone methylation structure in ESCs has
been discovered to be associated with the poised state
of cell lineage-specific genes [25]. Moreover, the per-
formance of cell lineage-specific genes always correlates
with the epigenetic memory observed in iPSCs [4, 5]. In
the present study, it was found that HPC/HSC-specific
genes possess a specific inverse occupancy of H3K4me2/
H3K4me3 and H3K27me3 patterns, which may partici-
pate in the observed different epigenetic transition in tran-
scription factor-mediated reprogramming of HPC/HSCs.
Further elucidation of the role of the inverse occupancy of
H3K4me2/H3K4me3 and H3K27me3 will undoubtedly
shed light on epigenetic reprogramming.
The present genome-wide analyses found that minor
transcriptional memory existed in one 4 N-incompoent
iPSC line; however, the minor transcriptional memory
had no influence on the hematopoietic lineage differenti-
ation capacity, which was not completely consistent with
the genome-wide epigenetic memory, as previously re-
ported [4, 5]. A possible explanation for this discrepancy
is the different results from other variations of these two
reprogramming systems. That is, although the lentivirus
vectors used here and in the previous study [4] are the
same, the copy number of proviruses may be different in
these two systems. In addition, the unique stoichiometry
of OSKM in the HPC/HSC reprogramming observed
here may also account for the quality of HPC/HSC-
iPSCs, as previously reported [26].
Concerning the cause of epigenetic memory, several
explanations have been proposed to answer this ques-
tion. DNA methylation has been reported to be associated
with the epigenetic memory observed in hematopoietic
cell-derived iPSCs [4]. It has also been reported that
low-passage iPSCs carry a significant epigenetic memory,
and in vitro cell culture can effectively eliminate genome-
wide epigenetic memory [5]. However, the low-passage
iPSCs used here did not show a biased differentiation
capacity to hematopoietic cells. In addition, miR-155 has
been shown to be associated with epigenetic memory in
hematopoietic cell-derived iPSCs [34]; however, a differen-
tial expression pattern of miR-155 was not observed in
iPSCs derived from the previously established sequential
reprogramming system [18]. Notably, the subtype of HPCs
used in that study (CD133+) was also different from the
one used here (c-kit+), in which miR-155 may not exert a
dominant role [34].
A recent study revealed that the reprogramming process
of HPC/HSCs activates a number of specific lncRNAs
[29], which is consistent with a previous study from this
research group [18]. Therefore, it is of interest to examine
the correlation between lncRNAs and epigenetic memory.
Notably, it has been found that the hematopoietic differ-
entiation capability of hiPSCs can be divided into a com-
mitment phase and a mature phase, which correlate with
the expression of IGF2 and de novo methylation in repro-
gramming, respectively [35]. Although there were some
variations in the expression of Igf2 in the iPSC lines used
here, no strict correlation between the expression of Igf2
and hematopoietic differentiation capability was ob-
served (data not shown). Nevertheless, in the current
study it was found that the minor transcriptional mem-
ory in 4 N-OFF HPC/HSC-iPSCs was associated with
the aberrant distribution of H3K27me3, which has re-
cently been found to be correlated with the epigenetic
reprogramming process in early embryos [36]. Future
investigation of the role of H3K27me3 distribution in
reprogramming will provide more information on the
molecular barriers to reprogramming.
The availability of high-quality iPSCs with full pluripo-
tency, no somatic memory and an unbiased differentiation
capacity is ideal for the potential therapeutic use of iPSCs.
The present study and our previous study [15] provide
(See figure on previous page.)
Fig. 4 Minor transcriptional memory in specific HPC/HSC-iPSC lines. a The “4 N-OFF” 20-HPC/HSC-iPSC-18 line is more similar to HPC/HSCs than
the “4 N-ON” 20-HPC/HSC-iPSC-16 line; note the similarity of its gene expression profile to that of the HPC/HSC genes with low expression. The
green box marks genes that are differentially expressed in the 20-HPC/HSC-iPSC-18 and 20-HPC/HSC-iPSC-16 lines. b The number of highly
expressed genes in the 20-HPC/HSC-iPSC-18 line that overlapped with highly expressed genes in the HPC/HSCs was greater than the number
that overlapped with genes with low expression in the HPC/HSCs. Sky-blue, HPC/HSC genes with low expression; pink, HPC/HSC genes with high
expression; orange, greater than a twofold change between the two cell lines (18 > 16). c The number of highly expressed genes in the 20-HPC/
HSC-iPSC-16 line that overlapped with genes with low expression in the HPC/HSCs was greater than the overlap with the HPC/HSC highly
expressed genes. The top ten most common enriched GO term categories represented by these genes are plotted. Sky-blue, HPC/HSC genes with
low expression; pink, HPC/HSC genes with high expression; pea green, greater than a twofold change between the two cell lines (16 > 18). d
Epigenetic modifications in the 332 overlapping genes in the 20-HPC/HSC-iPSC-18 and 20-HPC/HSC-iPSC-16 lines were compared. The distribution
of normalized counts for 20-HPC/HSC-iPSC-18 over 20-HPC/HSC-iPSC-16 in the TSS ± 2 kb regions from 332 overlapping genes and from 500
randomly selected genes was plotted (boxplot in R). The horizontal dashed line indicates no difference in the epigenetic modifications between
20-HPC/HSC-iPSC-18 and 20-HPC/HSC-iPSC-16; positive values indicate increased amounts of the modification in 20-HPC/HSC-iPSC-18, and
negative values indicate increased amounts of the modification in 20-HPC/HSC-iPSC-16. HPC/HSC hematopoietic progenitor and stem cell, iPSC
induced pluripotent stem cell
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evidence that HPC/HSCs are amenable to reprogram-
ming into high-quality iPSCs with full pluripotency,
minor transcriptional memory and unbiased differenti-
ation potential; however, somatic memory seems to be
inherent to transcription factor-mediated reprogram-
ming for the existence of minor transcriptional mem-
ory. Further studies on the reprogramming of HPC/
HSCs or other progenitor cells will shed new light on
reprogramming mechanisms and provide more alterna-
tives to obtain high-quality iPSCs.
Conclusions
HPC/HSCs undergo a unique reprogramming process
under the sequential reprogramming system we estab-
lished, which is different from that of MEFs. Genome-
wide analyses revealed that there is no detectable
epigenetic memory in HPC/HSC-iPSCs; nevertheless,
very minor transcriptional memory was observed in
one specific 4 N-incompetent type of iPSC, which resulted
from the aberrant distribution of H3K27me3 in the region
of the transcription start sites (TSS). However, the minor
transcriptional memory had no impact on the differenti-
ation of HPC/HSC-iPSCs into hematopoietic progenitors
and mature hematopoietic cells.
Additional files
Additional file 1: Figure S1. The expression of SSEA-1 in ESCs and iPSCs
after 8 days of co-culture with OP9 stromal cells. In the first column, ESCs
and iPSCs that were cultured on feeder cells for 8 days were isolated by SSC
(side scatter) and SSEA-1. In the second column, ESCs or iPSCs that were co-
cultured with OP9 stromal cells for 8 days were isolated by SSC and SSEA-1.
APC adipose progenitor cell, MEF mouse embryonic fibroblast, HPC/HSC
hematopoietic progenitor and stem cell, iPSC induced pluripotent stem cell,
SSC side scatter. (TIF 2617 kb)
Additional file 2: Figure S2. Analysis of the differentiation potential of
HPC/HSC-iPSCs into hematopoietic cells by flow cytometry. In the first
column, cells were isolated based on size, as indicated by SSC and FSC
(forward scatter). In the second column, GFP-negative cells were further
selected. In the third column, c-Kit and Sca-1 double-positive (c-Kit+Sca-1
+) cells were isolated. In the fourth column, c-Kit+Sca-1+ cells were further
divided into CD34+ and CD34- subpopulations. APC adipose progenitor
cell, MEF mouse embryonic fibroblast, HPC/HSC hematopoietic progenitor
and stem cell, iPSC induced pluripotent stem cell, SSC side scatter, FSC
forward scatter, APC allophycocyanin, PE-Cy7 phycoerythrin-Cy7, CD
cluster of differentiation. (TIF 3169 kb)
Additional file 3: Figure S3. No transcriptional memory in MEF-iPSCs.
(A) 10-MEF-iPSC-37 was indistinguishable from 10-MEF-iPSC-42 at the level
of global gene expression. Cor Pearson correlation coefficient, P P value,
X, Y log expression value. (B) No clustering of gene expression was ob-
served in 10-MEF-iPSC-37 and 10-MEF-iPSC-42. (C) No functional GO term
enrichment was observed between 10-MEF-iPSC-37 and 10-MEF-iPSC-42.
APC adipose progenitor cell, MEF mouse embryonic fibroblast, HPC/HSC
hematopoietic progenitor and stem cell, iPSC induced pluripotent stem
cell. (TIF 3267 kb)
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